You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 山東新華製藥飆升47%,7日內股價暴漲141%,公司旗下布洛芬等新冠防治藥需求激增
uSMART盈立智投 12-12 14:34

12月12日消息,$山東新華製藥股份(00719.HK)$持續走高,截至發稿,該股漲超47%,報12.54港元。

值得注意的是,該股此前已多日連漲,7個交易日內累計漲幅超141%。

消息面上,目前,隨着國內多地調整優化新冠防疫政策,全國進入疫情居家防控新時期,布洛芬等新冠病毒防治藥物的市場需求急劇增加。12月8日,國務院聯防聯控機制發佈了《新冠病毒感染者居家治療常用藥參考表》。山東新華製藥生產的布洛芬、對乙酰氨基酚、阿司匹林、氯雷他定、西替利嗪等藥物均在目錄內。

新華布洛芬片1981年在國內首家上市,有0.1g和0.2g兩個規格,2020年首家通過了仿製藥一致性評價,解熱鎮痛效果明顯。

山東新華製藥公司稱正積極配合國家防疫政策有關要求,生產車間多條智能化生產線開足馬力,加班加點生產布洛芬片、維生素C片等市場急需藥品,全力保障市場供應。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account